PMID- 29573236 OWN - NLM STAT- MEDLINE DCOM- 20190212 LR - 20220409 IS - 1743-7563 (Electronic) IS - 1743-7555 (Linking) VI - 14 IP - 6 DP - 2018 Dec TI - Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC. PG - 446-452 LID - 10.1111/ajco.12870 [doi] AB - AIM: Patients with advanced nonsquamous nonsmall cell lung cancer (NSCLC) who experienced progression with two or more lines chemotherapy have no treatment options that clearly confer a survival benefit. As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, apatinib has a certain antitumor effect for various solid tumors. The present study evaluated the efficacy and safety of apatinib in advanced nonsquamous NSCLC as salvage treatment in Chinese real-world practice. METHODS: Twenty-eight patients were enrolled in this observational study from October 2015 to May 2017. Progression-free survival (PFS) and overall survival (OS) were graphed by Kaplan-Meier curve and intergroup comparisons were carried out by log-rank test. Objective response rate (ORR), disease control rate (DCR) and adverse effects (AEs) were also evaluated. RESULTS: Seven patients obtained partial response, and 18 obtained stable disease, representing an ORR of 26% and a DCR of 93%. Median PFS and OS were 3 (95% confidence interval [CI] 2.6-3.4) and 7.4 (95% CI 1.3-13.5) months, respectively. The efficacy analysis showed that Eastern Cooperative Oncology Group (ECOG) performance status 0-1 was correlated with prolonged OS and PFS (P < 0.05), and hypertension during apatinib treatment was correlated with prolonged OS (P < 0.05). Cox regression showed that ECOG performance status (P < 0.01) (RR = 0.231) (95% CI 0.083-0.642) and hypertension during apatinib treatment (P = 0.05) were predictive indicators for apatinib treatment. Grade 3-4 AEs with incidences of 10% or greater were hypertension (21%), hand-foot syndrome (14%) and proteinuria (11%) which could be relieved by dose reduction. CONCLUSION: In conclusion, apatinib has a certain therapeutic effect in patients with advanced nonsquamous NSCLC. ECOG performance status and hypertension during apatinib might be predictive indicators for treatment efficacy. CI - (c) 2018 John Wiley & Sons Australia, Ltd. FAU - Wu, Di AU - Wu D AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Liang, Li AU - Liang L AD - Department of Tumor Chemotherapy and Radiation Sickness, Third Hospital, Peking University, Beijing, China. FAU - Nie, Ligong AU - Nie L AD - Department of Pulmonary and Critical Care Medicine, Peking University First Hospital, Beijing, China. FAU - Nie, Jun AU - Nie J AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Dai, Ling AU - Dai L AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Hu, Weiheng AU - Hu W AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Zhang, Jie AU - Zhang J AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Chen, Xiaoling AU - Chen X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Han, Jindi AU - Han J AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Ma, Xiangjuan AU - Ma X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Tian, Guangming AU - Tian G AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Han, Sen AU - Han S AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Long, Jieran AU - Long J AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Wang, Yang AU - Wang Y AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Zhang, Ziran AU - Zhang Z AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Xin, Tao AU - Xin T AD - Department of Medical Oncology, the 2nd Affiliated Hospital of Harbin Medical University, Harbin, China. FAU - Fang, Jian AU - Fang J AUID- ORCID: 0000-0002-1077-3686 AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China. LA - eng GR - Anti-Cancer Association Foundation of China/ PT - Journal Article PT - Observational Study DEP - 20180324 PL - Australia TA - Asia Pac J Clin Oncol JT - Asia-Pacific journal of clinical oncology JID - 101241430 RN - 0 (Antineoplastic Agents) RN - 0 (Pyridines) RN - 5S371K6132 (apatinib) SB - IM MH - Aged MH - Antineoplastic Agents/*therapeutic use MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology MH - Female MH - Humans MH - Lung Neoplasms/*drug therapy/pathology MH - Male MH - Pyridines/*therapeutic use MH - Safety MH - *Salvage Therapy MH - Survival Rate MH - Treatment Outcome OTO - NOTNLM OT - angiogenesis inhibitors OT - apatinib OT - efficacy OT - lung cancer OT - safety EDAT- 2018/03/25 06:00 MHDA- 2019/02/13 06:00 CRDT- 2018/03/25 06:00 PHST- 2017/11/02 00:00 [received] PHST- 2018/02/11 00:00 [accepted] PHST- 2018/03/25 06:00 [pubmed] PHST- 2019/02/13 06:00 [medline] PHST- 2018/03/25 06:00 [entrez] AID - 10.1111/ajco.12870 [doi] PST - ppublish SO - Asia Pac J Clin Oncol. 2018 Dec;14(6):446-452. doi: 10.1111/ajco.12870. Epub 2018 Mar 24.